The pharmaceutical distribution industry is closely watching the development of a national licensure standard that could reshape compliance requirements for wholesalers and third-party logistics providers.
Kala Shankle, JD, Vice President of Regulatory Affairs at the Healthcare Distribution Alliance, has emerged as a central voice in the debate over how national licensure standards should be structured.
Her remarks are connected to discussions at HDA’s 2026 Traceability Seminar, where a panel titled “Beyond Traceability: Preparing for National Licensure Standards” addressed the future of distributor licensing frameworks.
The core question facing the industry is whether a federal baseline standard can genuinely reduce the compliance burden that wholesale distributors and 3PLs currently face across different states.
One of the most significant concerns raised in the discussion is whether individual states will retain the authority to layer additional requirements on top of any federal standard that is established.
If states are permitted to add their own requirements beyond the federal baseline, the result could be increased compliance complexity rather than the simplification that a national standard is intended to deliver.
Timing is also identified as a critical factor in determining whether a national licensure framework can be successfully implemented across the distribution sector.
Industry stakeholders have long dealt with a patchwork of state-level licensing rules, each carrying its own set of requirements, timelines, and renewal processes that create operational strain for companies operating nationally.
A workable national standard would need to account for the wide variation currently embedded in state regulatory systems while providing enough uniformity to make compliance meaningfully simpler for distributors.
The Healthcare Distribution Alliance has positioned itself as a key advocacy body in pushing for a national approach, with Shankle’s regulatory expertise playing a prominent role in shaping the industry’s arguments.
Whether Congress or federal regulators move to establish such a standard remains an open question, but the pressure from distribution industry groups is growing as supply chain complexity continues to increase.
The outcome of these discussions will likely have significant implications for how pharmaceutical products are tracked, distributed, and licensed across the United States in the years ahead.